ANNOUCEMENT: Teleflex has entered into a definitive agreement to divest our Interventional Urology portfolio, including the UroLift System™, Barrigel™ rectal spacer, Deflux™ injectable gel, and Solesta™ bulking agent, to Intersurgical®. This transaction is expected to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions.
We’re excited about this opportunity and remain committed to providing the same high-quality products, reliable service, and on-time delivery our customers expect. We will keep our physicians and patients informed throughout the transition. Please feel free to contact your sales representative with any questions or concerns.
CONTROL MATTERS
CONTROL
MATTERS
Barrigel™ rectal spacer is the only sculptable spacer that gives you control over the shape and placement of the implant.1-5 Physician-controlled spacing provides confidence in achieving safe, symmetric and stable space.1,2
Hear from BARRIGEL PHYSICIANS*
“I have found that Barrigel spacer removes the element of uncertainty from rectal spacing. It allows me to carefully plan and adjust the placement of the gel and provide my patients with the best chance to eliminate rectal toxicity. It has already made a huge difference to my prostate cancer patients!”
– Suraj Singh, MD,
Radiation Oncologist, Director at Parkview Comprehensive Cancer Center
Hear from BARRIGEL PHYSICIANS*
“In my experience, Barrigel spacer is safer due to the ability to control its location and alter its placement during the procedure. This allows us to have a more uniform result in tougher cases where another procedure could result in delay of care.”
– Varun Sundaram, MD,
Urologist, Urology Austin
*This information reflects the personal experiences and professional medical opinions of the featured healthcare providers. Results may vary. All featured physicians are paid consultants of Teleflex.
SAFETY AND EFFICACY
MATTER
SAFETY AND EFFICACY
MATTER
Barrigel spacer is
proven superior
in the reduction of acute grade 2+ GI toxicity compared to control.1
Throughout the Barrigel Pivotal Trial, there were
zero
Barrigel-related
adverse events.1
SYMMETRY MATTERS
SYMMETRY
MATTERS
Customize the implant with sculptable gel to ensure optimal coverage.1,2,4 In the Barrigel Pivotal Trial, 95.6%** of implants were centered on the midline.2
95.6%

Results may vary.
**In a separate, directly analogous secondary analysis of data from the Barrigel pivotal trial, Barrigel symmetry results were compared to those of SpaceOAR, as reported in Fischer-Valuck BW et al. Pract Radiat Oncol (2017), using the same methodology used in that study. Information provided for educational purposes only. No head-to-head study has been performed. Results from different clinical studies are not directly comparable.
STABILITY MATTERS
STABILITY
MATTERS
Barrigel maintains stable rectal spacing.2 Even as Barrigel spacer gradually resorbs, shape and separation are maintained, on average, through 3 months.1,2 There were zero reports of implant migration in the Barrigel Pivotal Trial.1
IMMEDIATELY POST-INJECTION

3 MONTHS POST-INJECTION

Results may vary.
References
1. Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).†§
2. Svatos M, Chell E, King MT et al. Med Phys (2024).†§
3. Williams J, Mc Millan K, Chao M et al. J Med Imag Radiat Sci (2022).§
4. Gejerman G, Goldstein MM, Chao M et al. Pract Radiat Oncol (2023).§
5. Data on file. As of 4/01/2025.
† Study sponsored by Palette Life Sciences, now part of Teleflex.
§ One or more of the authors are paid consultants of Teleflex.
APM1026A